FOLH1 and prostate carcinoma: Our previous work showed that prostate cancer cells with moderate to high levels of PSMA expression could be effectively targeted by peptide 563 (P563; GRFLTGGTGRLLRIS), a highly selective PSMA-targeting peptide (Shen et al., 2013).